Revolution Medicines Inc (RVMD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $36.09B
Last updated: Nov 17, 2026 at 4:43 PM ET
Revolution Medicines Inc (RVMD) Statistics
Revolution Medicines (RVMD) has a market cap of $36.09B and an enterprise value of $35.96B. It kept -946.82% of revenue as net income over the last 12 months. Its share count is up 13.59% from a year earlier.
Total Valuation
Enterprise value is 0.35% below the market cap, as cash exceeds debt.
| Market Cap | $36.09B |
|---|---|
| Enterprise Value | $35.96B |
| Latest price (Nov 17, 2026) | $162.69 |
Key Dates
The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 177.0x and 14.6x. Its year-end P/S ranged from 28.0x to 249.4x from 2020 to 2024.
| P/S Ratio | 177.0x |
|---|---|
| Forward P/S | 57.7x |
| P/B Ratio | 14.6x |
| P/TBV Ratio | 15.0x |
Price Statistics
The stock is up 140.13% over 52 weeks and trades 15.58% below its 50-day average.
| Beta (1Y) | 1.31 |
|---|---|
| 52-Week Change | +140.13% |
| 1-Month Change | -10.68% |
| 3-Month Change | -24.21% |
| 6-Month Change | +10.45% |
| 5-Year Change | +550.05% |
| Total Return (1Y) | +140.13% |
| Total Return (3Y CAGR) | +96.81% |
| Total Return (5Y CAGR) | +40.17% |
| Return vs SPY (1Y) | +118.95% |
| Max Drawdown (1Y) | -26.43% |
| Max Drawdown (3Y) | -48.63% |
| Sharpe Ratio (1Y) | 1.32 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $192.71 |
| 200-Day Average | $160.55 |
| 52-Week Range | $69.50 to $224.31 |
| RSI (14 Days) | 35.4 |
| Average Volume (20 Days) | 2.39M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 8.36x current liabilities, and total debt is 0.20x shareholder equity.
| Current Ratio | 8.36x |
|---|---|
| Quick Ratio | 8.34x |
| Debt / Equity | 0.20x |
| Interest Coverage | -23.31x |
Returns and Efficiency
Return on invested capital is -52.09% over the last 12 months, against a 5-year average of -35.45%.
| Return on Equity (ROE) | -77.89% |
|---|---|
| Return on Assets (ROA) | -43.47% |
| Return on Invested Capital (ROIC) | -52.09% |
| ROE (5Y Average) | -37.42% |
| ROA (5Y Average) | -29.73% |
| ROIC (5Y Average) | -35.45% |
| Asset Turnover | 0.06x |
| Inventory Turnover | 0.06x |
| Receivables Turnover | 1.71x |
| Cash Conversion Cycle | -99161 days |
Scores
RVMD has an Altman Z-Score of 9.17, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 9.17 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $197.56M over the last 12 months is down 24.48% from the 12 months before.
| Revenue | $197.56M |
|---|---|
| Revenue Growth (YoY) | -24.48% |
| Gross Profit | $192.53M |
| Operating Income | -$1.69B |
| Pretax Income | -$1.87B |
| Net Income | -$1.87B |
| Reported EPS (TTM) | -$8.39 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 55.81% of the $4.30B in total assets.
| Cash and Equivalents | $615.91M |
|---|---|
| Total Debt | $487.88M |
| Net Cash | $128.03M |
| Net Cash Per Share | $0.60 |
| Working Capital | $3.50B |
| Shareholder Equity | $2.40B |
| Book Value Per Share | $11.17 |
| Tangible Book Value | $2.33B |
| Tangible Book Per Share | $10.85 |
| Total Assets | $4.30B |
| Total Liabilities | $1.90B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $9.45M of capital spending, operating cash flow left -$1.44B of free cash flow.
| Operating Cash Flow | -$1.43B |
|---|---|
| Capital Expenditures | $9.45M |
| Free Cash Flow | -$1.44B |
| FCF Per Share | -$6.72 |
| Depreciation and Amortization | $17.81M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -852.98%.
| Gross Margin | 97.45% |
|---|---|
| Operating Margin | -852.98% |
| Pretax Margin | -948.02% |
| Net Margin | -946.82% |
| FCF Margin | -729.31% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -18.56% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -18.71% |
Dividends and Yields
RVMD does not pay a dividend. Its free cash flow yield is -4.12%.
| FCF Yield | -4.12% |
|---|---|
| Buyback Yield | -6.91% |
| Shareholder Yield | -6.91% |
Peer Position
Against 11 similar companies, RVMD has the 2nd highest P/S.
P/S RatioPeer median 17.5x
ROICPeer median 4.83%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +25.96%
| P/S Ratio | 177.0x vs 17.5x median |
|---|---|
| ROIC | -52.09% vs 4.83% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -24.48% vs +25.96% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RVMD
What is RVMD's market cap?
Revolution Medicines has a market cap of $36.09B. Its enterprise value, which adds debt and subtracts cash, is $35.96B.
How many shares of RVMD are outstanding?
Revolution Medicines has 214.95M shares outstanding. The count is up 13.59% from a year earlier.
Does RVMD pay a dividend?
No. Revolution Medicines does not pay a dividend.
How much debt does RVMD have?
Revolution Medicines has $487.88M of total debt and $615.91M of cash and equivalents, a net cash position of $128.03M.
RVMD pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors